Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In vitro activities of contezolid (MRX-I) against drug-sensitive and drug-resistant Mycobacterium tuberculosis

21 Sept 2023

Abstract excerpt

ABSTRACT A novel oxazolidinone for the treatment of Mycobacterium tuberculosis has been developed, but the activity of contezolid (MRX-I) still needs to be clarified. In this study, we isolated Mycobacterium tuberculosis from 48 clinical patients with pulmonary tuberculosis. Roche drug susceptibility tests identified drug-sensitive and 39 drug-resistant M. tuberculosis isolates. Drug susceptibility assays...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Diagnosis and treatment of tuberculosis
Share to Mycobacterium research and diagnosis
Share to Tuberculosis Research and Epidemiology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37732805
DOI: 10.1128/spectrum.04627-22

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In vitro activities of contezolid (MRX-I) against drug-sensitive and drug-resistant Mycobacterium tuberculosisPMID 37732805Read ↗

Novel oxazolidinones harbor potent in vitro activity against the clinical isolates of multidrug-resistant Mycobacterium tuberculosis in ChinaSemantic proximity Read ↗

Contezolid can replace linezolid in a novel combination with bedaquiline and pretomanid in a murine model of tuberculosisSemantic proximity Read ↗

Contezolid can replace linezolid in a novel combination with bedaquiline and pretomanid in a murine model of tuberculosisSemantic proximity Read ↗

Drug Degradation Caused by mce3R Mutations Confers Contezolid (MRX-I) Resistance in Mycobacterium tuberculosis.Semantic proximity Read ↗

Drug degradation caused by <i>mce3R</i> mutations confers contezolid (MRX-I) resistance in <i>Mycobacterium tuberculosis</i>Semantic proximity Read ↗

A Novel Oxazolidinone, Contezolid (MRX-I), Expresses Anti-Mycobacterium abscessus Activity In VitroSemantic proximity Read ↗

Comparative In Vitro Drug Susceptibility Study of Five Oxazolidinones Against Mycobacterium tuberculosis in Hainan, ChinaSemantic proximity Read ↗

<i>In Vitro</i> efficacy comparison of linezolid, tedizolid, sutezolid and delpazolid against rapid growing Mycobacteria isolated in Beijing, ChinaSemantic proximity Read ↗

Multicentre evaluation of in vitro activity of contezolid against drug-resistant Staphylococcus and Enterococcus.Semantic proximity Read ↗

Comparison of In Vitro Activity and MIC Distributions between the Novel Oxazolidinone Delpazolid and Linezolid against Multidrug-Resistant and Extensively Drug-Resistant Mycobacterium tuberculosis in China.Semantic proximity Read ↗

Comparison of the in vitro activity of linezolid, tedizolid, sutezolid, and delpazolid against rapidly growing mycobacteria isolated in Beijing, ChinaSemantic proximity Read ↗

In Vitro Efficacy Comparison of Linezolid, Tedizolid, Sutezolid and Delpazolid Against Rapid Growing Mycobacteria Isolated in Beijing, ChinaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.